AstraZeneca Commits $200 Million to Tempus AI Over Five Years
Key Facts
Tempus AI and AstraZeneca AB signed an amendment on Nov. 16 extending their services agreement through Dec. 31, 2031, with AstraZeneca committing to total fees of $200 million over the renewal term. The amendment takes effect on Jan. 1, 2027, and sets a target annual spend of $40 million on Tempus’ current and future products and services. The agreement sets minimum fees of $32 million in each calendar year of the renewal term. These terms allow the commitment to be spread across the agreement’s years rather than treated as a single payment. The renewal extends a master services agreement dating to Nov. 17, 2021.
The agreement’s terms show that reaching the target total depends on the level of fees accrued during the renewal term. If total fees are less than $200 million at the end of the fifth year, the agreement automatically extends for one additional year to address the shortfall. That makes the end of 2031 the point for assessing how much of the commitment has been met, with the term potentially extending through Dec. 31, 2032 if the condition applies. AstraZeneca also retains the right to terminate the agreement for convenience at any time. If part of the financial commitment remains unmet upon termination, it must pay the outstanding shortfall.
Before the amendment, AstraZeneca’s minimum commitment under the existing agreement was $220 million through Dec. 31, 2028, with an option for the company to raise it to $320 million over that period. The renewal therefore comes within an existing contractual relationship between the parties, rather than as a new agreement separate from their current collaboration. The comparison shows that the amendment adds a renewal term and new spending terms to a framework that ran through the end of 2028. The new $200 million commitment applies to the renewal term and should not be added to figures from the previous agreement as a single commitment. The amendment sets the annual minimum and the mechanism for addressing any shortfall in total fees.
The agreement comes as Tempus reported third-quarter 2026 revenue of $411.5 million, up 23% from the same period in 2025. Oncology business volume rose 32% during the quarter, while net loss narrowed to $14.9 million from $80 million in the third quarter of 2025. The company also raised its fiscal 2026 revenue forecast to a range of $1.60 billion to $1.605 billion, representing annual growth of about 25%. These results provide financial context for renewing a commercial relationship covering Tempus products and services. They do not change the fee terms set out in the amendment between the parties.
Tempus announced separate agreements with AstraZeneca and Pathos in April 2025, valued at $200 million, for data licensing and model development as part of work on a multimodal foundation model in oncology. A later filing said Pathos would pay $200 million in data licensing fees over three years, including an upfront payment of $50 million paid by April 2025. Those earlier arrangements are separate from the current renewal fees, although they overlap with the broader collaboration on oncology data. When the original collaboration was announced, an AstraZeneca official said that analyzing large volumes of data with AI “is changing cancer drug discovery and clinical development.” The official added that the work aims to deepen understanding of tumor biology and strengthen predictive preclinical models.
Tempus AI shares closed at $63.43 on Nov. 17, 2026, according to EL7 data. No verified reading of AstraZeneca’s share price on Nov. 18 is available in the supplied data. Tempus’ recorded share price came after the amendment was signed the previous day, while the renewal terms take effect at the start of 2027. Actual fees remain tied to the products and services AstraZeneca buys and to the limits and mechanisms set out in the agreement. The filing sets the end of the core renewal term at Dec. 31, 2031, with a potential additional year if total fees do not reach the specified level.